N. Seth Berry

Background

About N. Seth Berry

Selecting the right dose, population, study, program, and portfolio design are some of the most significant challenges facing pharmaceutical companies today. Where traditional drug development has taken an empirical best-guess approach, the future lies in quantitative decision making through computer modeling and simulation. To make quick critical decisions that optimize resources and returns, an integrated suite of model-based drug development and clinical trial services is necessary in an organization.This is a considerable challenge for many biopharma companies. Not only is the therapeutic expertise and clinical trial infrastructure required to successfully navigate the development process, but significant technical / methodological capabilities are also necessary to succeed in this environment. With the arrival of low-cost cloud computing that provides state-of-the-art high performance computational capabilities with open-source software, a new level playing field is emerging. By taking this calculated approach to drug development, companies are finding value and giving their molecules, studies, programs, and overall portfolio the best chance of success.